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ABSTRACT: 
In vitro selection strategies are powerful tools for the identification of nucleic acids with 
unsuspected activities. Their successful application during last two decades has positioned 
these technologies among those most promising for the development of therapeutic and 
diagnostic agents. Aptamers are DNA or RNA molecules with special conformational features, 
able to efficiently bind to a target molecule. They are obtained by SELEX, a particular in vitro 
selection strategy, and have found utility during last years as a novel class of pharmaceuticals 
compounds. This review summarizes the progress made in the use of aptamers as therapeutic 
agents, paying special attention to those examples that have concluded in pharmacological 
formulations currently included in preclinical and clinical trials. 
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1. INTRODUCTION: 
The structural flexibility of nucleic acids, particularly RNA, results in their great functional 
versatility. Besides their well known function as key elements in the storage and transmission of 
the genetic information, nowadays it is assumed the participation of the RNA in a variety of 
biological functions that position nucleic acids in the centre of the essential cellular processes. 
This structural diversity has been successfully exploited for the in vitro identification and 
development of RNA and DNA molecules exhibiting, a priori, unsuspected functions. For this 
purpose, technologies known as in vitro selection and evolution strategies have been developed 
and applied during the last 20 years (reviewed in (Breaker, 1997; Burke and Berzal-Herranz, 
1993; Gold et al, 1995; Marton et al, 2010; Romero-López et al, 2007; Wilson and Szostak, 
1999)). Although all the strategies respond to the common general scheme represented in 
Figure 1a, they are designed on-demand according to the needs or interests of the researcher 
to end isolating RNA or DNA molecules exhibiting a desired phenotype from a large pool of 
variants. 
Specific and efficient binding of nucleic acids to a target molecule is a phenotype that has 
attracted much attention, most likely due to the further potential blocking effect on the target 
function. RNA or DNA molecules that efficiently interact with a specific molecule are named 
aptamers. The isolation of aptamers is performed by the application of a particular in vitro 
selection methodology, known as SELEX (Systematic Evolution of Ligands by Exponential 
enrichment) (Tuerk and Gold, 1990). This process consists of iterative series of synthesis, 
binding, positive selection and amplification steps over a randomized oligonucleotides pool to 
yield a population enriched in those molecules able to bind to the desired target molecule 
(Figure 1b). During this selection procedure, the recovered molecules can also be counter-
selected against a non-desired target in order to deplete the non-specific binders. The 
exploitation of this strategy has allowed for the identification of RNA or DNA molecules with 
potential clinical applications for a great variety of diseases (Ni et al, 2011). From basic 
research to preclinical and clinical studies, aptamers have shown to be promising candidates to 
develop pharmaceutical compounds. This review will summarize the current state of the art in 
this field, focusing on the ongoing clinical trials. 
 
2. APTAMER STABILIZATION: 
From a wide point of view, nucleic acid-based therapeutics, particularly RNA-based treatments, 
have important challenges to overcome, such as specific cell targeting, delivery and 
stabilization. The latter is mostly relevant in the case of inhibitor RNA molecules, mainly due to 
the highly abundant cytoplasmic and serum ribonucleases. This hurdle has been successfully 
solved by the development of modified nucleotides, which can be incorporated at precise 
positions during the chemical synthesis with minimal interference in the desired activity. Besides 
preventing degradation by exo- and endonucleases, chemical modifications may improve 
pharmacokinetic and pharmacodynamic properties of the nucleic acid, while reducing the 
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immunogenicity (reviewed in (Wang et al, 2011)). Thus, most of the aptamers with potential 
clinical application have been subjected to these chemical substitutions (see section 4).  
One of the main challenges for the practical use of modified aptamers has been the 
implementation of the chemical synthesis to get modified nucleotides susceptible to be inserted 
into the aptamers. Advances during last years have increased the efficiency and reliability of the 
manufacturing process, thus reducing the production costs. Theoretically, incorporation of 
modified nucleotides follows two well-defined strategies: 
1) During the SELEX step, by their inclusion during the initial RNA library synthesis step. This 
approach allows for the performance of the selection procedure in the presence of the chemical 
substitution, thus minimizing potential steric hindrance and favoring the acquisition of the 
functional three dimensional conformation by the aptamer. Modifications include changes in the 
backbone and/or the sugar moiety, and can be added during the transcription step by 
conventional or specifically modified T7 RNA polymerases (Burmeister et al, 2005; 
Chelliserrykattil and Ellington, 2004; Green et al, 1995; Jellinek et al, 1995; Kato et al, 2005; Lin 
et al, 1996; Ruckman et al, 1998).  
First generation of modified nucleotides included the replacement of the non-bridging oxygen 
atoms in the phosphate linkage by sulfur atoms (Figure 2A). This substitution has been widely 
employed in antisense oligonucleotides-based therapeutics, and to a lesser extent, in aptamers 
(King et al, 2002; Tam et al, 1999). The main disadvantage of this strategy is the marked 
decrease in the inhibitor specificity. Further advances performed on oligonucleotide chemistry 
prompted the development of second generation molecules containing chemical modifications 
affecting to the ribose moiety at the 2’ hydroxyl group: 2’-O-methyl, 2’-O-fluoro and 2’-O-
methoxyethyl sugar substitutions (Figure 2a). They overcome many of the drawbacks detected 
for the phosphorothioate compounds and often provide increased aptamer efficiency and even 
a higher thermal stability of the duplex (Botkjaer et al, 2012; Burmeister et al, 2005; Darfeuille et 
al, 2002; Rhie et al, 2003; White et al, 2008). These features have also been subsequently 
improved with the development of chemical analogs of nucleic acids. Among them, the so-
called LNA (locked nucleic acid) are of particular interest. LNA nucleosides contain a methylene 
linkage between the 2’-O and the 4’-C of the ribose molecule, which locks the sugar moiety into 
the energy-favorable C3’-endo conformation (Singh et al, 1998). LNA-modified oligonucleotides 
show high thermal stability when complexed with their DNA/RNA target, with increasing melting 
temperatures up to 10 ºC compared to unmodified duplexes (for a review, see (Barciszewski et 
al, 2009)). These chemical and biophysical properties also confer to LNAs high affinity and 
specificity for their targets. Hence, LNA-aptamers can be considered as the third generation of 
RNA-derivative drugs.  
In contrast to all these chemical substitutions, spiegelmers are obtained by SELEX where the 
target is the chiral mirror of the natural form. Then, the isolated D-RNA molecules can be 
converted to the L-RNA form to assess the recognition of the wild-type protein. The resulting 
aptamers are enantiomers of natural RNAs with increased nuclease resistance due to the 
stereo-selectivity of natural ribonucleases (Wilson and Keefe, 2006).  
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2) Post-selection editing process by site-specific engineering. This approach is preferably used 
for the incorporation of chemical substitutions that cannot be added during in vitro RNA 
synthesis, such as fluorophores, peptides, lipids and polysaccharides conjugates (Figure 2b). 
The addition reaction is usually performed at the 3’ and/or 5’ termini of the nucleic acid 
molecule, thus minimizing potential disruptions of the aptamer folding. These kind of conjugates 
have already been successfully used for the development of aptamer-based optical sensors 
detecting specific molecules (drugs as cocaine, cellular or viral protein factors, nucleotides,…) 
(Citartan et al, 2012) and for the engineering of cell and tissue specific oligonucleotide drugs 
delivery (for a review, see (Zhou and Rossi, 2011)). 
It is especially interesting the conjugation with polyetilenglicol moieties (PEG). The covalent 
linking of PEG chains, named PEGylation, has become a leading drug modification approach 
during last two decades. The addition of PEG provides important advantages to the carrier 
therapeutic compound, such as longer in vivo half-life, reduction of aggregates formation and 
low immunogenicity (Healy et al, 2004). Firstly tested in proteins, the PEGylation technology 
arrived to the aptamer field, yielding effective formulations that are currently being tested in 
clinical trials (see section 4) (Boomer et al, 2005).   
 
3. DEVELOPING APTAMERS FOR THEIR THERAPEUTIC USE: 
The potential use of aptamers as therapeutic agents was discerned since their discovery at 
1990 (Tuerk and Gold, 1990). Unlike other RNA tools, such as antisense oligonucleotides, 
ribozymes and siRNAs, aptamers work by the recognition of both the primary structure and the 
three dimensional conformation of the target, thus providing higher specificity than their 
counterparts (Darfeuille et al, 2006). This feature is also companied by low immunogenicity and 
toxicity, thus giving further advantages to aptamers over other therapeutic agents, as 
antibodies. Furthermore, the in vitro obtaining procedure greatly simplifies the efficiency and 
manufacturing process. This section will summarize the main recent advances in the preclinical 
studies performed with aptamers and current aptamer-based drugs research. 
 
3.1. Antiviral aptamers: 
Targeting viral factors has become one of the most popular aptamer therapeutic uses, since 
they can interfere at any stage of the viral cycle, including entry, translation, replication, 
packaging and budding. The first viral target chosen for the aptamers isolation was the viral 
polymerase, largely due to its innate ability for interacting with nucleic acids. The pioneer study 
performed by Tuerk et al. (Tuerk and Gold, 1990) not only rendered efficient aptamers for the 
T4 phage DNA polymerase, but also informed about the nature and composition of the protein 
domain involved in the initiation of replication. This work set the basis for further investigations 
about the potential of human virus proteins as efficient targets. During last years, this has been 
a leading proposal for the development of novel combinatorial therapeutic strategies based on 
drugs cocktails containing conventional viral replication inhibitors and nucleic acid-based 
inhibitors. This would greatly improve the efficacy of current antiviral treatments and would 
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diminish the appearance of escape viral mutants. Many efforts have been made to target 
protein factors involved in different steps of the viral cycle (reviewed in (Binning et al, 2012)):  
1) Virus entry: HIV targets helper T-cells by glycoprotein 120 (gp120). The use of gp120 as 
protein target for aptamers allows, not only for the inhibition of viral entry, but also for the 
specific delivery of other antiviral compounds (Dey et al, 2005; Khati et al, 2003; Mufhandu et al, 
2012; Neff et al, 2011; Sayer et al, 2002; Zhou et al, 2008; Zhou et al, 2011a; Zhou et al, 2011b; 
Zhou et al, 2009). 
2) Replication: viral RNA-dependent RNA polymerases have been a common target for the 
identification of aptamers. These proteins ususally share classical reverse transcriptase 
features with unique conformational and functional properties. Hence, the identification of 
aptamers against them has been a major goal, not only from a clinical point of view, but also for 
the investigation of their exceptional functioning. Aptamers targeting HCV NS5B protein 
effectively inhibited its function in vitro and in infected cells, demonstrating the feasibility of this 
approach for the design of novel anti-HCV drugs (Bellecave et al, 2008; Biroccio et al, 2002; 
Jones et al, 2006). To date, however, information about the replication mechanism is still scant. 
In the case of HIV, aptamers against the reverse transcriptase (RT) have also been extensively 
reported. The application of in vitro selection strategies demonstrated that HIV-1 RT is an 
effective antiviral target, even in those viral strains that are resistant to conventional non-
nucleoside inhibitors (Chaloin et al, 2002; Chen and Gold, 1994; DeStefano and Cristofaro, 
2006; DeStefano and Nair, 2008; Joshi and Prasad, 2002; Li et al, 2008; Mosing et al, 2005; 
Schneider et al, 1995; Tuerk et al, 1992). Some of these aptamers were chemically modified by 
the inclusion of phosphorothioate nucleotides to yield efficient inhibitor RNA molecules in vitro 
(DeStefano and Nair, 2008). 
3) Protein synthesis and maturation: many viruses have developed alternative translational 
mechanisms to that employed by the cellular cap-mRNAs, thus rendering a candidate target for 
virus inhibition. For example, HCV genome is a single stranded, plus polarity RNA molecule 
containing in its 5’ end an internal ribosome entry site (IRES), which directs protein synthesis by 
a cap-independent pathway. This region exhibits a high sequence and structure conservation 
rate that has been widely exploited as potential therapeutic target (for a review, see (Romero-
Lopez et al, 2006)). Aptamers against isolated functional domains of the IRES have been 
shown to act as efficient inhibitors of viral translation, both in vitro and in cell culture (Kikuchi et 
al, 2003; Kikuchi et al, 2005; Kikuchi et al, 2009; Tallet-Lopez et al, 2003). These studies 
demonstrated the efficacy of targeting functional genomic domains in RNA virus and served as 
starting point for the development of novel strategies combining two or more inhibitor RNA 
molecules targeting the whole IRES (Romero-López et al, 2005; Romero-López et al, 2012; 
Romero-López et al, 2009; Romero-López et al, 2007). These compounds interfered with HCV 
translation in the range of nanomolar, providing the proof of concept for the engineering of new 
chimeric nucleic acid-based inhibitors.    
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After their synthesis, protein products may need further processing and maturation. This has 
been also considered an interesting hot point for the control of the viral infection. In the case of 
HCV, the NS3 protein displays protease and helicase activities in two well-defined regions, 
playing key functions for the viral polyprotein maturation and viral RNA synthesis (Tanji et al, 
1994; Wardell et al, 1999). In the past, efforts were focused on the development of selection 
strategies for the identification of aptamers targeting different functional domains (Fukuda et al, 
2004; Fukuda et al, 2000; Nishikawa et al, 2004; Nishikawa et al, 2003). These findings 
prompted an initial attempt of engineering dual-aptamers, generated by the combination of two 
independently isolated aptamers with different target sites, linked by a non-related sequence 
(Umehara et al, 2005). The chimeric molecules retained both aptamer specificities and acted as 
efficient inhibitors of protease activity and virus replication in cell culture.    
4) Encapsidation: the isolation of aptamers targeting viral core proteins is an interesting strategy 
for the investigation of the packaging process and the signals that govern it. For example, RNA 
aptamers against the nucleocapsid protein were isolated by different groups (Berglund et al, 
1997; Kim and Jeong, 2003; Kim and Jeong, 2004) and proved efficient inhibition of the HIV 
genomic RNA packaging stage in cell culture. 
 
3.2. Aptamers in oncology: 
Cancer has been classically considered the result of genetic alterations affecting to essential 
signaling pathways, thus conferring proliferative and invasive properties to the carrier cell 
(Hanahan and Weinberg, 2000). These particular features exhibited by the malignant cell may 
be exploited by aptamers to specifically target and inhibit tumor progression. Aptamers have 
been developed against a variety of cancer targets, including extracellular ligands, cell surface 
proteins and intracellular factors.  
The isolation of cell-type specific aptamers, mostly directed against cell surface receptors, 
achieves the direct action over the desired target cell (Cerchia and de Franciscis, 2007). It also 
provides specific delivery for a wide variety of drugs and reagents and its active accumulation 
when combined with a cell-specific aptamer, thus improving the efficacy of the treatment. To 
date, numerous aptamers directed against a specific cell type or tissue have been isolated by 
conventional SELEX methodologies or through innovative cell or tissue-SELEX processes. The 
latter are becoming emerging methods for the identification of aptamers targeting specific and 
likely unknown, cell surface molecules (Phillips et al, 2008). Their main advantage is that 
selected molecules recognize the native state of the ligand and even could likely differentiate 
not only cancer cells from non-tumoral tissues, but also between different types of cancer. 
Nevertheless, the high complexity and diversity of the cell and tissue surface conditions the 
selection pressure to avoid high diversity in the isolated aptamer pools. Hence, despite of the 
potential of the method, care should be taken in the subsequent analysis and validation of the 
selected aptamers.    
The receptors for tyrosine kinase (RTK) are candidate targets since they appear constitutively 
activated in a variety of cancers, such as multiple endocrine neoplasia type 2A and 2B 
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syndromes and in familiar medullary thyroid carcinoma (Putzer and Drosten, 2004). The 
development of the live cell-based selection techniques (Cerchia et al, 2005) allowed for the 
isolation of the efficient inhibitor D4, a modified 2’-fluoropyrimidine RNA aptamer able to interact 
with the extracellular protein domain and interfere with the subsequent signaling pathway, 
preserving its activity in tissue-like microenvironments (Vento et al, 2008).   
A recent application of aptamers is their use as drug carriers. Since Lupold et al. (Lupold et al, 
2002) identified two RNA aptamers against the extracellular portion of the prostate-specific 
membrane antigen (PSMA), great efforts have been made to engineer aptamer-based 
therapeutic reagents that specifically target PSMA-positive malignant cells. The combination of 
these aptamers with small interfering RNAs (siRNAs) (Chu et al, 2006) targeting prostate 
cancer-specific prosurvival genes involved in the tumor progression, such as bcl2 and plk1, 
showed several advantages (Chu et al, 2006; Kim et al, 2010; McNamara et al, 2006). These 
constructs promote the efficient cellular uptake, simplify the compound formulation and present 
low toxicity compared to other delivery systems as cationic lipids, peptides or even viral vectors. 
In addition, they provide a feasible tool for the clinical use of siRNAs.   
 
3.3. Anticoagulant aptamers: 
Anticoagulants are a major class of pharmaceutical agents that can be used to prevent clotting 
events during certain clinical situations or for the treatment of cardiovascular diseases. The 
most commonly used reagent, heparin, may unleash serious secondary effects, such as 
hemorrhages, decrease in the platelet number and even allergies. Thus, the discovery of new 
anticoagulant drugs was a major goal during many years. In this context, aptamers appeared as 
a good alternative to classical drugs. 
Thrombin protein is a preferred target for the development of anticoagulant compounds. This 
factor is a serine protease with a key role in hemostasis by the activation of procoagulant 
factors, which greatly amplify the coagulation reaction. The use of aptamers able to control this 
cascade was glimpsed in the early 1990’s, with the isolation of a DNA aptamer that interfered 
with the proteolytic activity of thrombin (Bock et al, 1992). The great potential of this compound 
as anticoagulant prompted further pharmacokinetic and pharmacodynamic tests in different 
animal models (Griffin et al, 1993). These initial trials showed a proper dose-response relation 
between the aptamer administration and the anticoagulation activity. Importantly, maximum 
therapeutic effect was assessed at ten minutes after infusion, thus reflecting a short half-life. 
This feature could be very useful for the aptamer application to extracorporeal circuits. The 
results derived from the subsequent Phase I clinical trials were unsuccessful (Kim et al, 2008), 
but they opened a wide field for the development and engineering of novel efficient 
anticoagulant aptamers. The isolation of nuclease resistant, modified RNA-based aptamers 
against thrombin by other groups has confirmed the suitability of this strategy (Jeter et al, 2004; 
Kubik et al, 1994; White et al, 2001). Furthermore, these investigations pointed to the heparin 
binding site within thrombin as the optimal target region for the efficient aptamer interaction and 
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the consequent inhibitory activity. All together, these findings may promote the rational design 
and engineering of novel aptamer-based antithrombin drugs. 
One of the main causes for morbidity during the anticoagulant treatments is bleeding. Thus, the 
idea of using aptamer compounds as anticoagulants has become even more attractive by the 
incorporation of RNA aptamer-based antidotes, which could provide the safest mechanism for 
the control of the drug activity (see section 4.3.1) (Rusconi et al, 2002). More recently, the 
development and engineering of light-inducible anti-thrombin aptamers is a promising strategy 
for the improvement of pre-existing compounds (Buff et al, 2010).  
 
4. PRECLINICAL AND CLINICAL TRIALS: 
The above mentioned reports provided the proof of concept to accomplish further validation for 
the use of aptamers as therapeutic reagents. Despite numerous obstacles, more than ten 
aptamer-based therapies have reached the clinical trial step. This section will summarize the 
main advances in the field of aptamer therapeutics for the treatment of cellular diseases (Table 
1). 
 
4.1. Anti-angiogenic aptamers:  
Numerous pathological processes, such as tumorigenesis, ocular neovascular diseases or 
inflammatory events are intrinsically linked to the angiogenesis phenomenon. Hence, the control 
of the neovascularization events in these patients is a good alternative to interfere with the 
progress of the disease. 
4.1.1. Therapy against VEGF: Pegaptanib. 
VEGF is a pro-angiogenic factor, which can be produced as four principal isoforms, being 
VEGF165 the most abundant in serum (Ferrara, 2004). 
Three different SELEX process were carried out by different groups of the NeXstar 
Pharmaceuticals Company to identify aptamers targeting VEGF. First of them, reported on 
1994, described the isolation of aptamers blocking VEGF activity in vitro, confirming the 
potential suitability of the strategy (Jellinek et al, 1994). Subsequent approaches made use of 
amino-modified aptamers to increase their stability and resistance to nuclease attack (Green et 
al, 1995). Finally, the use of fluoro-oligonucleotides set the basis for the further development of 
Pegaptanib. 
Pegaptanib (commercially available as Macugen, OSI Pharmaceuticals/Pfizer) is the first nucleic 
acid that was approved for its use in clinical applications. This compound proceeds from a 2’-
fluoropyrimidine RNA aptamer identified in 1998 by Ruckman et al. (Ruckman et al, 1998) from 
a conventional SELEX procedure using as target VEGF165. Three different aptamer families 
were isolated with binding affinities to VEGF in the range of low picomolar. Representative 
molecules from each group were truncated to get the minimal region able to bind to VEGF and 
fully modified with 2’-O-methyl purines and a 3’-3’ linked deoxythimidine cap, with the aim of 
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increasing their intracellular stability. One of these aptamers, t44-OMe, appeared as the most 
efficient inhibitor of vascular leakage from dermal microvessels following injection into guinea 
pigs. It was further modified by the addition of 40 kDa PEG at the 5’ end to get the current 
Pegaptanib compound. Though it was observed an evident reduction in the binding affinity to 
VEGF after all these modifications, the resulting compound was even a more effective inhibitor 
than its unmodified counterparts. This is likely due to a longer tissue residence and serum half-
life. Subsequent works investigating the pharmacodynamic properties of Pegaptanib in 
monkeys demonstrated that the biologically active aptamer could be detected in the vitreous 
humour of the eye even 28 days after administration, without detecting significative secondary 
symptoms (Drolet et al, 2000; Tucker et al, 1999). These studies prompted the initiation of the 
clinical trials, which finally led to the approval of Pegaptanib in December 2004 for its 
therapeutic use in patients with age-related macular degeneration (AMD).  
4.1.2. Other antiangiogenic targets:  
1) Aptamers against the complement system: ARC1905. 
The complement system is a part of the innate immune system, which is stimulated during 
sepsis to generate a series of activation products that finally unleash the cleavage of the C5 
molecule, generating the anaphylatoxin C5a and C5b. This determines the recruitment of 
inflammatory cells and the liberation of pro-angiogenic factors, such as VEGF (for a review, see 
(Ward, 2010)). This mechanism plays a key role in the progression of numerous 
pathophysiologic disorders. Interfering with C5 activity has been largely proposed as a good 
strategy for the treatment of pathologies related to the vascularization and inflammatory 
processes. Different methods for blocking this cascade have been reported, including the use of 
neutralizing antibodies and pharmacological inhibitors (reviewed in (Woodruff et al, 2011)). 
The well-known advantages of aptamers as therapeutic compounds, and the previous 
successful use of Pegaptanib as antiangiogenic drug, promoted the development of anti-C5 
RNA-based inhibitors. The application of a SELEX methodology from a starting pool of 2’-
fluoropyrimidine-modified oligonucleotides  yielded seven aptamers able to interact with C5 with 
a Kd in the range of nanomolar (Biesecker et al, 1999). These molecules effectively interfered 
with the C5 hemolytic activity in serum. Furthermore, they efficiently blocked downstream steps 
in the complement cascade governed by C5. A truncated version of one of these aptamers was 
further optimized by the application of a second selection procedure. This experiment yielded 
the 2’-fluoroaptamer ARC1905, with increased affinity by C5. Subsequent conjugation with PEG 
at the 5’ end and 3’ capping achieved a stable molecule, which is currently being tested in 
clinical trials (Phase I) for the treatment of AMD by Ophthotech.  
2) Targeting of platelet-derived growth factor (PDGF): E10030. 
Platelet-derived growth factor (PDGF) is an essential, ubiquitous mitogen and chemotactic 
factor required for the normal development of the heart, ear, central nervous system (CNS), 
kidney, eye and brain. In adults, it contributes to the normal maintenance of kidney, pancreas 
and CNS, and also regulates the blood vessels formation. Its overproduction in the absence of 
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exogenous stimulation leads to several diseases, such as atherosclerosis, glomerulonephritis, 
renal failure, glioblastoma, medulloblastoma and fibrosis (reviewed in (Reigstad et al, 2005)).  
The critical function of PDGF during neovascularization events promoted its selection as 
potential target to interfere with the angiogenesis process. In 1996, Green et al. identified a 
group of DNA molecules able to interact with PDGF-AB with subnanomolar affinity (Green et al, 
1996). One of these aptamers, E10030, was reduced to the minimal active region, and 
subsequently modified by 5’-PEG addition and 3’-capping to improve the exonuclease 
resistance. It is currently being assayed in AMD patients, in a Phase II clinical trial, by 
Ophthotech.   
 
4.2. Aptamers as antiproliferative agents: 
4.2.1. AS1411: 
The antiproliferative DNA aptamer AS1411 was identified from a cell-based screening of 
guanosine-rich oligonucleotides that interfered with cellular propagation (Bates et al, 2009b). 
The initial pool of oligonucleotides was shown to form homoquadruplex stabilized by G-quartets, 
the essential requirement for their interaction with the nucleolin protein on the cell plasma 
membrane (Bates et al, 2009a). Nucleolin is a multifunctional protein that is highly expressed by 
cancer cells, both intracellularly and on the cell surface, and plays a critical role in the activation 
of the transcriptional factor NF-B (Girvan et al, 2006). AS1411 has proved its efficiency in 
many different animals and preclinical cancer models, and is currently being tested in Phase II 
clinical trials by Antisoma Research.  
4.2.2. Spiegelmers for cancer therapies: 
Many attempts have been accomplished for the development of spiegelmers targeting 
malignant cells. Two compounds, NOX-A12 and NOX-E36, are currently being tested in Phase I 
clinical trial for their potential as antiproliferative drugs by Noxxon Pharma AG. They bind 
chemokines ligand 12 and 2, respectively, which are mainly involved in tumor metastasis and 
inflammation (Sayyed et al, 2009). Both of them are conjugated to a 3’-PEG molecule. NOX-
A12 is being assayed for the treatment of lymphoma, multiple myeloma and hematopoietic stem 
cell transplantation, whereas NOX-E36 is being administered to Type 2 Diabetes mellitus 
patients that suffer glomerulosclerosis for the treatment of tissue injury and inflammation. 
 
4.3. Anticoagulant aptamers in clinical trials: 
4.3.1. Aptamers targeting Factor IXa: REG1. 
In 2002, Rusconi et al. (Rusconi et al, 2002) described the identification of the 2’-fluorpyrimidine 
aptamer RB006 targeting factor IXa, a key partner in the blood clotting formation. A chimeric 
molecule was further engineered by the addition of a 2’-methoxy-RNA oligonucleotide 
complementary to a portion of the RB006, thus achieving a regulatory sustainable system for 
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the anticoagulant activity. Conjugation of this construct with polyetilenglicol (PEG) or cholesterol 
(Rusconi et al, 2004; Rusconi et al, 2002) significantly increased its serum half-life in different 
animal models. The resulting construct, named REG1, was further tested by Regado 
Biosciences Inc. in clinical trials. Recently, in a Phase IIa assay, REG1 showed well tolerability 
in patients suffering percutaneous coronary intervention, with no angiographic thrombotic 
complications and good reversible response mediated by the antidote domain (Becker and 
Chan, 2009; Cohen et al, 2010). These promising results have prompted the following Phase IIb 
study, currently ongoing.   
4.3.2. Inactivation of the von Willebrand factor for the control of the coagulation cascade: 
ARC1779. 
Platelet adhesion and aggregation in sites of vascular injury, stenosis and endothelial 
denudation is dependent on the von Willebrand factor (vWF). As well as its immediate potential 
as anticoagulant target, it has great potential in combined therapies for the treatment of acute 
coronary syndromes. 
ARC1779 is a chimeric DNA/RNA aptamer that binds to vWF with high affinity. This compound 
contains 13 unmodified 2’-deoxynucleotides and 26 2’-O-methylnucleotides. It is capped in its 5’ 
end by a PEG moiety of 20 kDA and by a deoxythimidine nucleotide placed at the 3’ termini. All 
these modifications contribute to increase the aptamer serum stability (Gilbert et al, 2007). 
Pharmacodynamic properties of ARC1779 were firstly assayed in a Phase I clinical trial by 
Archemix Corporation, showing dose dependence with respect to the area distribution and low 
toxicity. These results promoted the initiation of the subsequent Phase II clinical tests (Spiel et 
al, 2009). Injection of ARC1779 demonstrated to be an effective approach for the inhibition of 
vWF and vWF-dependent platelet function in patients with acute myocardial infarction.  
4.3.3. Clinical trials with anti-thrombin aptamers: NU172. 
Nu172 is a DNA aptamer selected to bind and interfere with the thrombin function (Waters et al, 
2009). Te application of a conventional SELEX method yielded a pool of parental, potentially 
inhibitory aptamers. One of them was subsequently truncated to the minimal core active 
aptamer. This compound, without further modifications, is currently being tested in Phase II 
clinical trials for anticoagulation in heart disease therapies by ARCA Biopharma. Unfortunately, 
preliminary results have shown a limited efficacy of NU172.  
 
4.4. Procoagulant aptamers:  
Hemophilia A and B are bleeding disorders characterized by deficiencies in coagulation factor 
VIII (FVIII) and factor IX (FIX), respectively, resulting in abnormally prolonged bleeding. Factor 
replacement has been the most widely used treatment for these patients. However, it has been 
described that around 15% of the patients may develop a rejection reaction by the production of 
antibodies able to neutralize the replacing proteins (Srivastava and Group, 2005). Hence, the 
combination of these therapies with bypassing agents is a major goal. It is well-known that in 
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hemophilic patients the extrinsic coagulation pathway, negatively regulated by the tissue factor 
pathway inhibitor (TFPI) is intact (Crawley and Lane, 2008). The inhibition of TFPI would be, 
therefore, a suitable strategy to improve the blood clotting propagation.  
Waters et al. described in 2011 (Waters et al, 2011) the isolation of a modified RNA-aptamer 
targeting TFPI by using a conventional SELEX method. The starting library was composed by a 
randomized mix of oligonucleotides containing deoxycytidine and 2’-O-methyl-guanosine, -
adenine and -thymidine. The parent aptamer was subsequently truncated to define the minimal 
region able to interact with TFPI, and modified by the addition of a 3’-deoxythymidine cap and a 
5’-hexylamine linker with a 20 kDa PEG moiety, to finally generate ARC19499. This molecule 
efficiently binds to TFPI, promoting the thrombin generation in hemophilia plasma. In monkeys 
treated with neutralizing antibodies, it corrected clotting and bleeding times. These results 
demonstrate the suitability of this strategy for its use with hemophilic patients in a combined 
therapy. Archemix Corp. is currently tested its activity in humans in a Phase II clinical trial. 
 
5. PERSPECTIVES: 
The emergence of the in vitro selection methodologies and particularly the isolation of 
aptamers, as novel useful tools for the development of therapeutics and diagnostics has moved 
to several companies for the exploitation of these technologies. The most significant companies 
holding key patents and/or license for the therapeutic application of the aptamer technology are 
OSI Pharmaceuticals, Noxxon Pharma AG and Archemix Corp.  
Despite of the initial promising results offered by the use of Pegaptanib in AMD patients, it was 
replaced by a cheaper product, just two years after its approval. The new compound, though 
more effective than the aptamer drug, promoted important side-effects and was only tolerated 
by a low percentage of the affected individuals. New clinical trials were accomplished to further 
study the long-term pharmacodynamic features of Pegaptanib and its therapeutic potential for 
other clinical optic pathologies.      
The great advances carried out in the field of aptamers production and their clinical applications 
have demonstrated that interfering with therapeutic targets function may be achieved by small 
molecules. This may be an useful strategy to complement alternative therapies, such as the use 
of neutralizing antibodies. These approaches are currently being extensively investigated by 
several companies with the aim of improving the therapeutic response and the long-term 
effects, as well as minimizing the toxicity and secondary effects.   
In summary, aptamers provide a promising and unique tool for therapeutics. Given the fast 
progresses made in the field, it seems likely that in the next decade aptamers may be a 
common instrument for the clinical practice. 
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Table 1. Aptamers currently being tested in clinical trials. 
 
Pathway Target Aptamer Pathology Corporation Clinical Trial References 
Thrombin NU172 Heart disease ARCA Biopharma Phase II (Waters et al, 2009) 
vWF ARC1779 von Willebrand Disease Archemix Corp. Phase II 
(Gilbert et al, 
2007; Spiel et al, 
2009).  
Coagulation 
(inhibition) 
Factor IXa REG1 Cardiovascular diseases 
National Heart, 
Lung, and Blood 
Institute (NHLBI) 
Phase I 
(Rusconi et al, 
2004; Rusconi et 
al, 2002) 
(Becker and 
Chan, 2009; 
Cohen et al, 
2010). 
Coagulation 
(induction) TFPI ARC19499 Haemophilia Archemix Corp. Phase II 
(Waters et al, 
2011) 
Chemokine 
ligand 12 NOX-A12 
- Lymphoma 
- Multiple 
myeloma 
- Hematopoietic 
stem cell 
transplantation 
Noxxon Pharma 
AG Phase I 
(Sayyed et al, 
2009) 
Malignant cell 
proliferation 
Nucleolin AS1411 
Primary 
Refractory or 
Relapsed AML 
Antisoma 
Research Phase II 
(Bates et al, 
2009b) 
(Bates et al, 
2009a) 
(Girvan et al, 
2006). 
Inflammation Chemokine ligand 2 NOX-E36 
Type 2 Diabetes 
Mellitus 
Systemic Lupus 
Erythematosus 
Noxxon Pharma 
AG Phase I 
(Sayyed et al, 
2009) 
PDGF E10030 AMD Ophthotech Corporation Phase II 
(Green et al, 
1996) 
Angiogenesis 
VEGF EYE001 AMD OSI Pharmaceuticals 
Phase 
II/III 
(Ruckman et al, 
1998) 
(Drolet et al, 
2000; Tucker et 
al, 1999) 
Complement 
system C5 ARC1905 AMD 
Ophthotech 
Corporation Phase I 
(Biesecker et al, 
1999) 
 
AMD: Age-related macular degeneration; AML: Acute Myeloid Leukemia; PEG: Polyetileglicol; 
TFPI: tissue factor pathway inhibitor; VEGF: vascular endothelial growth factor; vWF: von 
Willebrand factor. 
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Figure legends: 
Figure 1. In vitro selection methods. A) General scheme of an in vitro selection procedure 
involving an RNA library. An RNA population containing active and inactive variants is subjected 
to a selective pressure. Active RNA molecules are selectively recovered and reverse 
transcribed. Amplification of the cDNA templates generates a DNA pool, which is transcribed to 
yield a new RNA population that can be sampled and subjected to further selection rounds if 
required. B) SELEX process. Identification of RNA aptamers targeting a specific ligand by the 
application of an in vitro selection method. Figure adapted from (Romero-López et al, 2007). 
Suppression of transcription and reverse transcription steps allows for the isolation of active 
DNA oligonucleotides. 
 
Figure 2. Chemical modifications. Diagram shows the most common chemical substitutions 
incorporated into synthetic oligonucleotides aimed to improve their pharmacodynamic 
properties. Pre-SELEX (A) and post-SELEX (B) modifications mentioned throughout the text are 
included. PEG, polyethilenglycol. 
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